Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease
- 1 January 2007
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 4 (1), 42-55
- https://doi.org/10.1038/ncponc0688
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's DiseaseNew England Journal of Medicine, 2005
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Kieferknochennekrosen als mögliche unerwünschte Wirkung von BisphosphonatenMund-,Kiefer- und Gesichtschirurgie, 2005
- Bisphosphonate und Osteonekrosen im KieferbereichMund-,Kiefer- und Gesichtschirurgie, 2005
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenNew England Journal of Medicine, 2004
- Efficacy of risedronate on clinical vertebral fractures within six monthsCurrent Medical Research and Opinion, 2004
- Bisphosphanates and Oral Cavity Avascular Bone NecrosisJournal of Clinical Oncology, 2003
- Hypocalcemia Following Pamidronate Administration for Bone Metastases of Solid Tumor: Three Clinical Case ReportsJournal of Pain and Symptom Management, 2003
- Cyclic Administration of Pamidronate in Children with Severe Osteogenesis ImperfectaNew England Journal of Medicine, 1998
- PATHOLOGIC FRACTURE DUE TO SEVERE OSTEOMALACIA FOLLOWING LOW‐DOSE DIPHOSPHONATE TREATMENT OF PAGET'S DISEASE OF BONEAustralian and New Zealand Journal of Medicine, 1983